VUF-11222

CAS No. 1414376-84-3

VUF-11222( —— )

Catalog No. M34735 CAS No. 1414376-84-3

VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 217 Get Quote
5MG 331 Get Quote
10MG 494 Get Quote
25MG 776 Get Quote
50MG 1067 Get Quote
100MG 1413 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VUF-11222
  • Note
    Research use only, not for human use.
  • Brief Description
    VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.
  • Description
    VUF 11222 (Compound 38) is a CXCR3 non-peptide-like agonist. VUF 11222 can be used in the study of inflammation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1414376-84-3
  • Formula Weight
    552.33
  • Molecular Formula
    C25H31BrIN
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C([N+](CC1=CC=C(C=C1)C2=C(Br)C=CC=C2)(C)C)C=3[C@]4(C(C)(C)[C@](C4)(CC3)[H])[H].[I-]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wijtmans M, et al. Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands. J Med Chem. 2012 Dec 13;55(23):10572-83.?
molnova catalog
related products
  • Delmetacin

    Delmetacin (Demethacin) is a non-steroidal anti-inflammatory compound with anti-inflammatory and analgesic activity and inhibitory effects on the CXC chemokine receptor CXCR1.

  • WZ811

    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.

  • SX-682

    SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.